Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information   
Inhaled Ventavis® (iloprost) Inhalation Solution Breathe In the Power of Prostacyclin In Pulmonary Arterial Hypertension (PAH) NYHA Class III or IV
     Dosage & Administration
PAH Pathways - Actelion Services & Support
Download 20 mcg/mL Medication Order Form
Download the
Ventavis Patient
Enrollment Forms

Dosage and Administration

  • Ventavis® (iloprost) Inhalation Solution should be taken 6 to 9 times per day (no more than once every 2 hours).1
  • Dosing recommended during waking hours (90% of clinical trial patients never inhaled Ventavis during sleeping hours).1
  • Ventavis is intended for inhalation administration via a breath-actuated pulmonary drug delivery system: the I-neb AAD System.
  • The first inhaled dose should be 2.5 mcg (as delivered at the mouthpiece).1
    • If the 2.5-mcg dose is well tolerated, dosing should be increased to 5.0 mcg and maintained.
    • If the 5.0-mcg dose is not tolerated, dosing should be reduced to and maintained at 2.5 mcg.
    • For patients maintained at 5 mcg who have repeatedly experienced extended treatment times, transition to 20 mcg/mL.
  • For each inhalation treatment, follow what is described in the Full Prescribing Information.
    • After each inhalation session, any solution remaining in the I-neb AAD System medication chamber should be discarded.
    • Use of remaining solution will result in unpredictable dosing.

The 20 mcg/mL concentration is intended for patients who are maintained at the 5 mcg dose and who have repeatedly experienced extended treatment times which could result in incomplete dosing. Ventavis 10 mcg/mL ampules are still available. Ventavis should be taken 6 to 9 times daily, at least 2 hours apart.1

Data based on an in vitro study with a manually generated 28.3-L/min, 15-sec inhalation cycle breathing pattern.

The I-neb AAD System is a registered trademark of Philips Respironics.

1. Ventavis (iloprost) Full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2009.



ACTELION